DNA hypermethylation of MAL gene may act as an independent predictor of favorable prognosis in patients with colorectal cancer
Open Access
- 1 September 2019
- journal article
- research article
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 8 (5) , 1985-1996
Abstract
Background: Aberrant DNA methylation could be used as biomarkers for colorectal cancer (CRC) detection and assessment of prognosis. The aim of our study was to investigate the potential possibility of MAL methylation as a prognostic biomarker for postoperative CRC patients. Methods: We followed up 298 sporadic postoperative CRC patients and detected MAL methylation in tumor tissues and adjacent non-tumor tissues by methylation-sensitive high resolution melting (MS-HRM) analysis. Univariate, multivariate Cox regressions were performed to evaluate the potential possibility of MAL methylation as a predictor of prognosis. Propensity score (PS) analysis was used to control confounders. Results: The MAL methylation level in adjacent non-tumor tissues was significantly lower than that in tumor tissues (PMAL methylation had no significant correlation with clinicopathologic characteristics. MAL hypermethylation was detected in 63.4% (189/298) tumor tissues. The overall 5-year survival rates in hypermethylation and hypomethylation group were 70.78% and 55.69% (P=0.007). MAL hypermethylation was significantly associated with a favorable clinical outcome, the hazard ratio (HR) were 0.650 [95% confidence interval (CI): 0.454–0.929, P=0.018], 0.613 (95% CI: 0.422–0.889, P=0.010) and 0.692 (95% CI: 0.481–0.996, P=0.047) in univariate, multivariate Cox and PS method, respectively. The subgroup analysis showed that MAL hypermethylation in CRC patients with lower diagnosis age (MAL hypomethylation patients. Conclusions: MAL was frequently hypermethylated in CRC tumor tissues. MAL hypermethylation might act as an independent prognostic predictor of survival advantage in postoperative patients with CRC.Keywords
This publication has 41 references indexed in Scilit:
- Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomasMolecular Cancer, 2011
- Genomic and Epigenomic Integration Identifies a Prognostic Signature in Colon CancerClinical Cancer Research, 2011
- Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature reviewInternational Journal of Cancer, 2010
- MAL promoter hypermethylation as a novel prognostic marker in gastric cancerBritish Journal of Cancer, 2008
- Hypermethylator Phenotype in Sporadic Colon Cancer: Study on a Population-Based Series of 582 CasesCancer Research, 2008
- Proteins that bind methylated DNA and human cancer: reading the wrong wordsBritish Journal of Cancer, 2008
- Hypermethylated MAL gene – a silent marker of early colon tumorigenesisJournal of Translational Medicine, 2008
- Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylationNucleic Acids Research, 2007
- Caveolin-1 and MAL are located on prostasomes secreted by the prostate cancer PC-3 cell lineJournal of Cell Science, 2004
- MAL gene expression in esophageal cancer suppresses motility, invasion and tumorigenicity and enhances apoptosis through the Fas pathwayOncogene, 2003